Subscribe to our Newsletters !!


    Group invulnerability as COVID-19 system unsafe, nations must make opportune mediations: CSIR

    Putting money on creating group insusceptibility to battle coronavirus is “too enormous a hazard” for any country and just opportune intercessions can alleviate the spread of COVID-19, Director General of the Council of Scientific and Industrial Research (CSIR) Shekhar Mande said. Group insusceptibility is accomplished when most of populace gets resistant to an irresistible malady,

    BD Announces Assay for Identification of COVID-19 Patients

    EYSINS, Switzerland, February 03, 2021/BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the CE mark of BD Multitest™ 6-Color TBNK Reagent with BD Trucount™ Tubes with expanded clinical application to help clinicians identify COVID-19 patients at increased relative risk of intubation with mechanical ventilation (IMV) and mortality at

    Study uncovers the complex cell mechanism of Ebola

    Mount Sinai researchers discovered the intricate cellular mechanisms of Ebola virus. This could help to explain the severe effects on people and provide potential treatment or prevention. The team published a study in mBio that showed how VP24, a protein from the Ebola virus interacts with the double-layered cell membrane (known as the nucleus) and

    Scientists test a library of lipid-based compounds to empower safe RNA drug delivery to Lungs

    Japan’s Hokkaido University researchers created and tested a collection of lipid-based compounds in order to deliver RNA drugs safely and effectively to the lungs. The findings were published in Materials Horizons. The COVID-19 pandemic response made it all more familiar with RNA vaccines. These vaccines carry genetic code into the cells, which triggers the production

    SMART and NTU Singapore develop a quick test kit to determine a person’s immunity against COVID-19 and its variants

    A team of scientists from the Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, and Nanyang Technological University, Singapore (NTU Singapore) has developed a quick test kit that can tell if a person has immunity against COVID-19 and its variants, based on the antibodies detected in a blood sample. Different from